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Despite advances in supportive care, infection remains a significant cause of morbidity 
and mortality post haematopoietic stem cell transplant (HSCT).  Impaired humoral 
immunity, marked by a decline in antibody titres to vaccine preventable diseases (VPD), 
is observed within months and may continue for years post-HSCT(1). HSCT recipients 
are at increased risk of morbidity and mortality from influenza virus infection and 
invasive pneumococcal disease(2,3), two relatively common VPDs. The impact of 
declining antibody titres post-HSCT on susceptibility to other VPDs is unclear, but cases 
of Haemophilus influenzae, pertussis, and measles are documented(4–6). It is therefore 
considered best practice to try and offer HSCT recipients the same level of protection 
against all VPDs as the general population, and immunogenicity studies have 
demonstrated that post-HSCT antibody titres can be boosted by vaccination(7–9). FACT-
JACIE International Standards for Haematopoietic Cellular Therapy require, therefore, 
that schedules are in place(10). To define this schedule of post-HSCT vaccination, UK 
HSCT programmes can refer to guidelines from several major societies, along with 
consensus conference proceedings and recommendations from national paediatric 
groups(11–14).  In the absence of supportive data, guidelines recommend standard 
vaccination schedules unmodified by disease indication, stem cell source or conditioning 
regimen, however the specifics of the schedules vary across these guidelines.     
 
We surveyed the adult and paediatric allogeneic HSCT programmes of the UK National 
Health Service (NHS) with the aim of assessing homogeneity of practice and 
determining how clinical care aligns with current evidence, recommendations and 
guidelines. We defined a Routine Vaccination Programme (RVP) as a ‘series of scheduled 
vaccinations administered after allogeneic HSCT as standard post-transplant care’ and 
developed a 25 question web-based survey, with questions grouped into four themes: 
RVP service organization, RVP vaccine selection, RVP commencement and delay, and 
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monitoring of response to vaccines.  Response options were mapped to current 
recommendations and guidelines, and asked specifically about current RVP practice.  
Respondents were advised to refer to local guidelines or standard operating procedures 
(SOP) when completing the survey.  The survey was developed in conjunction with an 
infectious disease physician, senior adult and paediatric alloHSCT physicians, and 
alloHSCT nurse specialists all with an interest and expertise in vaccination.   The survey 
was piloted with 5 HSCT specialists and optimized accordingly.  An invitation to 
participate was e-mailed by the British Society of Blood and Marrow Transplantation 
(BSBMT) to all 27 adult and 12 paediatric UK alloHSCT programme directors.  Directors 
were invited to complete the survey or delegate to the healthcare professional taking 
primary responsibility for RVP.  The survey was open between May and December 2015.  
 
100% of adult and 83% of paediatric HSCT programmes responded to the survey.  The 
age range of patients treated by paediatric programmes is 0-20 years. The majority of 
surveys were completed by HSCT programme directors (54%) or consultant grade HSCT 
physicians (30%), with the remainder completed by HSCT nurse specialists (8%), 
pharmacists (5%) or non-consultant grade physicians (3%).  95% of responding 
programmes were JACIE accredited having completed at least 1 cycle, with 5% working 
towards JACIE accreditation.   
 
All responding adult and paediatric programmes recommend a RVP for HSCT recipients.   
However, only a minority of adult (8%) and paediatric (10%) programmes offer 
vaccination on site; the remainder refer HSCT recipients to primary care for vaccine 
administration.  Nearly two-thirds (65%) of programmes do not maintain a record of 
vaccine administration in patients’ case notes.  RVP practice has been audited by 54% of 
HSCT programmes that maintain vaccination records compared to only 29% that do not. 
The survey did not enquire about the scope of audits undertaken. Most adult (97%) and 
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paediatric (80%) programmes maintain a document controlled SOP detailing RVP 
schedules.  Adult programmes mostly base RVP SOPs and/or RVP practice on 
international HSCT specific vaccination guidelines(11,12) (70%).  In contrast, paediatric 
programmes tend to use national HSCT specific guidelines(14) (60%), with a minority 
(10%) using international guidelines.  HSCT programmes were not asked to submit 
SOPs for analysis. 
 
Almost all adult and paediatric programmes recommend an inactivated vaccine 
targeting the VPDs covered by the UK NHS vaccination schedule: diphtheria-tetanus-
pertussis, Haemophilus influenzae B, pneumococcal, seasonal influenza virus, 
meningococcal and polio virus vaccines (Table 1).  The exception to this is the Human 
Papilloma Virus (HPV) vaccine, which is recommended for female HSCT recipients by all 
paediatric programmes but only 15% of adult programmes. Where a number of vaccine 
formulations are available, programmes vary in their selection with some 
recommending vaccines known to be poorly immunogenic in this patient group, for 
example the 23-valent pneumococcal polysaccharide vaccine.   In a minority of cases 
vaccine selection is left to the discretion of the administering primary care practitioner. 
In the UK, high risk individuals are immunized against Hepatitis B; a minority of adult 
(33%) and paediatric (20%) programmes recommend this vaccine as routine. Adult 
programmes appear cautious around administration of live attenuated vaccines, with 
only half recommending Measles-Mumps-Rubella (MMR) vaccines to measles 
seronegative patients. In contrast, all paediatric programmes recommend this vaccine.  
A minority (20%) of paediatric programmes, and no adult programmes recommend a 
live attenuated varicella vaccine to seronegative recipients.  
 
Programmes commence RVP at a range of time points from 3 to 18 months post HSCT 
(Table 2). 20% of paediatric programmes distinguish between recipients of related and 
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unrelated donors, commencing RVP in the former at 12, and the later at 18 months. 
Most adult programmes (74%) do not use a marker of immune reconstitution to guide 
initiation of RVP, while 70% of paediatric programmes use lymphocyte subsets alone 
(40%) or with immunoglobulin levels (30%).  
 
The approach to vaccination of HSCT recipients with chronic graft versus host disease 
(cGVHD) or on immunosuppressive therapy (IST) varies across programmes.  
Programmes were asked to indicate the lowest or ‘threshold’ cGVHD grade by NIH 
criteria, and lowest or ‘threshold’ combination of IST, that necessitates deferral of 
inactivated and live attenuated vaccines.  While the majority of paediatric (80%) and 
adult (74%) programmes defer inactivated vaccines if recipients have active cGVHD, the 
threshold grade prompting deferral varies (Table 2).  The remaining 20% of paediatric 
and 26% of adult programmes administer inactive vaccines to HSCT recipients with 
active cGVHD regardless of grade. All paediatric and the majority (78%) of adult 
programmes defer inactivated vaccines if recipients are on IST.  Again, there is no 
consensus on the lowest IST combination that necessitates deferral (Table 2). 
Concerning live attenuated vaccines, 19% of adult and 60% of paediatric programmes 
give moderate or severe cGVHD as the threshold grade for deferral, but would 
administer to recipients with mild cGVHD.  A single adult programme reports dual agent 
IST as the threshold combination for deferral of live attenuated vaccines, otherwise all 
programmes defer if recipients are taking any single agent IST including corticosteroids. 
 
Half of paediatric programmes, and 44% of adult programmes routinely monitor 
serological response to vaccinations.  30% of adult programmes monitor serological 
response to vaccine if clinically indicated.  Indications given are as follows:  illness from 
a VPD (100%), Ongoing IST (75%), active GVHD (38%).  All of the 30% of paediatric 
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programmes that monitor response if clinically indicated, give illness from VPD as the 
sole indication.   
 
With a 95% response rate, this survey provides a current and comprehensive picture of 
RVP practice across adult and paediatric UK NHS allogeneic HSCT programmes. A 
weakness of the survey format is that it relies on self-reporting, rather than independent 
verification of practice. Reassuringly, routine post-HSCT vaccination has been adopted 
by all responding adult and paediatric programmes, representing 100% and 83% of all 
UK allogeneic programmes respectively.  However, we identified variation across all 
survey themes.  This heterogeneity may be attributed to an evidence base insufficient to 
provide detailed practical guidance, conflicting recommendations between guidelines, 
tension between international recommendations and national vaccine licensing 
restrictions, and in some cases a lack of familiarity with current guidelines.  
 
Our findings highlight the need for review of local post-HSCT vaccination schedules 
alongside the current evidence base.  Areas that are particularly pressing include 
vaccine selection, and vaccination of HSCT recipients with cGVHD or on IST.  In the UK 
(and elsewhere), this may be best delivered at national level as a harmonized guideline 
and/or policy that synthesizes best practice recommendations and national licensing 
considerations, thereby providing HSCT programmes and primary care teams who 
administer vaccines a single reference source. In the UK national vaccination 
programmes are commissioned for delivery by primary care and most HSCT 
programmes refer recipients for vaccine administration.  A recent single centre audit 
reported that completion rate of vaccination schedules is low(15).  Given that many 
HSCT programmes are not maintaining records of vaccine administration, 
communication with primary care, monitoring and audit should form a central 
 7 
component of national guidelines, and may be facilitated by the inclusion of a 
vaccination checklist.  
 
In summary, this national survey has highlighted highly variable delivery of RVP across 
a national healthcare system, with limited quality assurance as to whether accepted 
practice recommendations are met.  Although there remains a clear need for robust data 
to better inform re-vaccination practice following HSCT, harmonized health service 
policies are warranted to ensure coordinated delivery of this important aspect of post-
transplant care by HSCT teams, patient referral centres and primary care.     
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